These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21054)

  • 61. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function.
    Prescott LF; Freestone S; McAuslane JA
    Br J Clin Pharmacol; 1993 Jan; 35(1):20-9. PubMed ID: 8448064
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.
    Huang W; Czuba LC; Isoherranen N
    J Pharmacol Exp Ther; 2020 Jun; 373(3):488-501. PubMed ID: 32198137
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The pharmacokinetics of Norpace.
    Karim A
    Angiology; 1975 Jan; 26(1 Pt 2):85-98. PubMed ID: 1090217
    [No Abstract]   [Full Text] [Related]  

  • 64. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human.
    Vree TB; Van Ewijk-Beneken Kolmer EW; Verwey-Van Wissen CP; Hekster YA
    Int J Clin Pharmacol Ther; 1994 Oct; 32(10):550-8. PubMed ID: 7834163
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
    Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP
    Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influence of renal failure on disopyramide pharmacokinetics [proceedings].
    Henry JA; Johnston A; Warrington SJ; Hamer NA
    Br J Clin Pharmacol; 1979 Apr; 7(4):427P-428P. PubMed ID: 444377
    [No Abstract]   [Full Text] [Related]  

  • 68. [Clinical pharmacology of anti-arrhythmia agents. I. Quinidine, procainamide and disopyramide].
    Witkowska M
    Kardiol Pol; 1981; 24(7):505-17. PubMed ID: 7024612
    [No Abstract]   [Full Text] [Related]  

  • 69. Effect of dose of charcoal on the absorption of disopyramide, indomethacin and trimethoprim by man.
    Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 1984; 26(6):761-7. PubMed ID: 6489417
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Study on transport of disopyramide into the intestinal lumen aimed at gastrointestinal dialysis by activated charcoal in rats.
    Arimori K; Nakano M
    J Pharm Pharmacol; 1989 Jul; 41(7):445-9. PubMed ID: 2570848
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Renal clearance of sulphinpyrazone in man.
    Lentjes EG; Russel FG; van Ginneken CA
    Eur J Clin Pharmacol; 1986; 31(4):473-8. PubMed ID: 3816927
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Influence of urinary pH on pethidine kinetics in healthy volunteer subjects. 2. A study of ten Chinese subjects.
    Chan K; Tse J; Jennings F; Orme ML
    Methods Find Exp Clin Pharmacol; 1987 Jan; 9(1):49-54. PubMed ID: 3573868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Saliva concentrations of disopyramide cannot substitute the drug's plasma concentrations.
    Cordonnier J; Van den Heede M; Heyndrickx A
    J Anal Toxicol; 1987; 11(4):179-81. PubMed ID: 3626531
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of changes in urine pH on plasma pharmacokinetic variables of ampicillin sodium in horses.
    Sarasola P; Horspool LJ; McKellar QA
    Am J Vet Res; 1992 May; 53(5):711-5. PubMed ID: 1326242
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Disposition of pethidine in man under acidic urinary PH. I. Plasma level and urinary elimination of pethidine and norpethidine.
    Chan K
    J Clin Hosp Pharm; 1981 Jun; 6(2):107-16. PubMed ID: 7343560
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Accumulation of a disopyramide metabolite in renal failure].
    Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Oral disopyramide dosage regimes in ischaemic heart disease.
    Bryson SM; Fotheringham GH; Struthers MG; Whiting B
    J Clin Hosp Pharm; 1982 Mar; 7(1):37-42. PubMed ID: 7096577
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of disopyramide on left ventricular performance: the relationship of free and total concentrations of the drug and of its mono-N-dealkylated metabolite to noninvasive indices of function.
    Holt GW; Norris RL; Ravenscroft PJ; Bett JH; Dryburgh LG; Boyle CM
    J Cardiovasc Pharmacol; 1983; 5(1):51-4. PubMed ID: 6186859
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite in plasma by gas-liquid chromatography.
    Aitio ML
    J Chromatogr; 1979 Dec; 164(4):515-20. PubMed ID: 541429
    [No Abstract]   [Full Text] [Related]  

  • 80. Clinical pharmacokinetics of disopyramide.
    Karim A; Nissen C; Azarnoff DL
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):465-94. PubMed ID: 6762414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.